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On September 18, 2007, a collaborative session between the
International Society for CNS Clinical Trials and Method-
ology andthe International Society for CNS DrugDevelop-
ment was held in Brussels, Belgium. Both groups, with
membership from industry, academia, and governmental
and nongovernmental agencies, have been formed to address
scientiﬁc,clinical,regulatory,andmethodologicalchallenges
in the development of central nervous system therapeutic
agents. The focus of this joint session was the apparent dim-
inutionofdrug-placebodifferencesinrecentmulticentertrials
ofantipsychoticmedicationsforschizophrenia.Tocharacter-
ize the nature of the problem, some presenters reported data
from several recent trials that indicated higher rates of pla-
cebo response and lower rates of drug response (even to pre-
viouslyestablished,comparatordrugs),whencomparedwith
earliertrials.Asameanstoidentifythepossiblecausesofthe
problem, discussions covered a range of methodological fac-
tors such as participant characteristics, trial designs, site
characteristics, clinical setting (inpatient vs outpatient), in-
clusion/exclusioncriteria,anddiagnosticspeciﬁcity.Finally,
possiblesolutionswerediscussed,suchasimprovingprecision
ofparticipantselectioncriteria,improvingassessmentinstru-
ments and/or assessment methodology to increase reliability
of outcome measures, innovative methods to encourage
greater subject adherence and investigator involvement, im-
proved rater training and accountability metrics at clinical
sites to increase quality assurance, and advanced methods
ofpharmacokinetic/pharmacodynamicmodelingtooptimize
dosing prior to initiating large phase 3 trials. The session
closed with a roundtable discussion and recommendations
fordatasharingtofurtherexplorepotentialcausesandviable
solutions to be applied in future trials.
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Introduction
Following the ‘‘Decade of the Brain,’’ the climate of sci-
entific understanding regarding the pathophysiological
mechanisms underlying diseases and dysfunctions of
the central nervous system (CNS) had never been better
for the development of therapeutic breakthroughs.
Nevertheless, presently approved treatments are, for
themostpart,uniformlyunabletoaddresstheunderlying
etiologyofthediseasestheyareaimedtotreat,providing,
at best, palliative symptomatic relief.
1 Moreover, despite
increasedscientificunderstandingandtremendousindus-
trial investment in the development of CNS therapeutics,
only 9% of the compounds that have entered phase 1 tri-
als in recent years have survived to launch.
2 Over 50% of
these failures, according to Hurko and Ryan,
2 were di-
rectly attributable to an inability to demonstrate efficacy
during phase 2 trials. This is an increase of 15% in phase
2 failures over the previous decade. Clearly, there is
a need for addressing the methodological obstacles
that are impeding progress in this critical sector of ther-
apeutic development.
The development of pharmacologic interventions to
treat CNS disorders is fraught with unique challenges
that often require highly specialized methodologies and
trial designs. In particular, existing forums have not
1To whom correspondence should be addressed; tel: 714-456-
8690; fax: 714-456-5967, UCI Neuropsychiatric Center, 101 The
City Drive South, Orange, CA 92868; e-mail: akemp@uci.edu.
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504adequately addressed the gaps or disconnects between
regulatory demands and requirements and clinical feasi-
bility in the CNS area. In contrast, the fields of oncology,
immunology, and cardiology have developed extensive
interactions among academics, regulators, and industry
scientists, and this process has significantly improved
clinical research in these disciplines. Therefore, in order
to address the obstacles confronting researchers pursuing
experimental CNS treatment modalities, 2 complimen-
tary organizations (the International Society for CNS
Clinical Trials and Methodology [ISCTM] and the Inter-
national Society for CNS Drug Development [ISCDD])
have been formed in recent years.
The focus of this joint session was on examining the
apparent diminution of drug-placebo differences (even
with previously established comparator drugs) that has
been observed in recent clinical trials of antipsychotic
medications for schizophrenia. Because the development
of antipsychotic medications is now entering a ‘‘third
generation,’’ this issue must be exhaustively reviewed
prior to launching additional multimillion dollar trials,
or new chemical entities may suffer from the same meth-
odological shortcomings that have apparently limited the
potentialforaccuratedeterminationsofefficacyoverpla-
cebo. The session was organized to present data regard-
ing drug-placebo differences over time, review probable
causes, and consider potential solutions that could be
implemented in future trials. The following is a summary
of the presentations and discussions from the session.
Nature of the Problem
Thesessionchairs,A.H.K.andN.R.S.,providedanover-
view of the issue and introduced its importance. To place
theissuewithinhistoricalcontext,L.A.providedareview
of how recent randomized controlled trials (RCTs) stand
in contrast with earlier studies particularly regarding pla-
cebo response levels. Drawing on data from trials con-
ducted between 1991 and 2006 (figure 1), the mean
reduction from baseline on the total score of the Positive
and Negative Syndrome Scale (PANSS
3) for participants
receiving placebo has increased across RCTs. There is
a significant correlation (R
2 = 0.55) between the amount
of reduction and the year the study was conducted.
L.A. also compared a phase 3 development program
conducted during the early to mid-1990s with a more re-
cent phase 3 program. This comparison showed that, by
and large, participants in the later RCTs had a signifi-
cantly larger response to placebo on both PANSS total
scores and Clinical Global Impression-Severity ratings
at 6 weeks, relative to baseline. As shown in figure 2,
the percentage of placebo-treated patients falling into re-
spective categories of change from baseline on total
PANSS scores shows a significant overall shift toward
greater improvement/less worsening at 6 weeks in later
trials compared with earlier trials. Paralleling this in-
creaseinplaceboresponse,L.A.alsoreportedareduction
in active drug response, further contributing to an overall
Fig. 2. The Percentage of Placebo-Treated Patients Falling into Respective Categories of Change From Baseline on Total Positive and
Negative Syndrome Scale (PANSS) Scores Shows Fairly Large Differences at Many Specific Levels and a Significant Overall Shift Toward
Greater Placebo Improvement and Less Placebo Worsening at 6 wk in Later Trials Compared With Earlier Trials.
Fig. 1.Mean ChangeFromBaseline in Total Positive andNegative
Syndrome Scale (PANSS) Scores for Subjects Receiving Placebo
Across Randomized, Double-Blind, Placebo-Controlled, Clinical
Trials Has Increased in the Direction of Greater Improvements,
Which Is Correlated With the Year That the Studies Were
Conducted.
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505diminishing of drug-placebo differences. These observa-
tions raise many questions: Have the populations in-
cluded in the trials changed? Are recent studies poorly
designed or executed? Has the disease itself or its diagno-
sis changed? Are the newer drugs simply less effective
than older compounds studied?
Further evidence for a diminishing of drug-placebo dif-
ferences in recent schizophrenia trials was also presented
by S.G.P. The results of a recent phase 3, randomized,
double-blind, placebo- and positive-controlled, multicen-
ter, efficacy, and safety trial provided evidence that the
reduction in drug-placebo difference is not only due to
increasesinplaceboresponsesbutthatdiminishedresponses
to active compounds has also contributed to the effect. As
shown in table 1, the overall mean change from baseline in
total PANSS scores for subjects receiving both active
compounds was not distinguishable from that of subjects
receiving placebo. S.G.P. pointed out that both compounds
h a ds h o w na ne f f i c a c ys i g n a li nearlier acute exacerbation
trials.One,theactivecomparator,wasawidelyusedantipsy-
chotic that is well accepted as safe and efficacious.
There were no obvious demographic differences
among the randomized groups. However, one potentially
important distinction within the groups may be relevant
as a potential source of the problem. Table 2 shows that
the subjects at sites outside of the United States had
slightly lower placebo response coupled with a notably
larger drug response to both active compounds. Subjects
from these sites (5 in Ukraine and 2 in Russia) also dis-
played higher (more severely ill) PANSS scores at base-
line. However, baseline severity does not account for the
difference in drug-placebo difference between US and
ex-US sites. Duration of illness, on the other hand, did
appear to have an impact; subjects whose current episode
of exacerbation exceeded 4 weeks at baseline displayed
consistently lower response to active drug, though pla-
cebo responses were mixed. Additional data from 3
RCTswere also presented toassess the impact ofwhether
the studies were conducted in the United States or other
locations. These data did not illustrate any consistent dif-
ferences in placebo responses.
In discussing the implications of these findings, meet-
ing attendees suggested additional participant character-
istics that should be examined. Prior exposure to newer
atypical antipsychotics may be relevant because the
prescription prevalence of these may differ within and
outside of the United States. An additional, related pos-
sibility raised was whether having more patients who are
pleased with their current medications might alter the po-
tential subject pool because fewer participants may seek
research opportunities in hopes of finding better treat-
ment. This also raised the question that ‘‘professional’’
research participants, increasingly common in the United
States and whose motivations may not stem solely from
a desire to find a more efficacious medication, may rep-
resent a potential source of higher placebo response due
to an apparent eagerness to please the investigators, in
hopes of returning for additional trials.
Findings of diminished drug-placebo differences are
not unique to schizophrenia RCTs, as was illustrated
by S.D., who presented an overview of efforts to resolve
similar challenges in the area of antidepressant drug de-
velopment. Many of the previous findings that have
served to draw attention to this question in antidepres-
sant RCTs and proposals for potential design or analytic
solutions were credited to the pioneering work spear-
headed by William Potter.
4–6
Table 1. Results From a Phase 3, Placebo-Controlled,
Antipsychotic Trial
Placebo Compound A Compound B
Number of patients 89 85 85
Mean PANSS total
score at baseline
85.9 87 87
Mean change from
baseline in PANSS
11.7 10.7 12.2
P value for change
(vs placebo)
NS NS
Note: PANSS, Positive and Negative Syndrome Scale; NS, not
significant.
Table 2. Results From a Phase 3 Antipsychotic Trial by Sites Within and Outside of the United States (US)
Sites outside of the US Sites within the US
Placebo Compound A Compound B Placebo Compound A Compound B
Number of patients 11 8 9 78 77 76
Mean PANSS total
score at baseline
99 96 98 84 86 86
Mean change from
baseline in PANSS
9.2 22.8 27.7 12.0 9.5 10.3
P value for change
(vs placebo)
.040 .093 NS NS
Note: PANSS, Positive and Negative Syndrome Scale; NS, not significant.
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cebo responsive’’ and often characterized by fluctuating
severity and spontaneous remission. As such, antidepres-
sant RCTs have always been particularly bedeviled by
poor drug-placebo differentiation. Similar to the findings
presented for schizophrenia trials, this phenomenon has
become increasingly more problematic in recent years.
Among the underlying issues that have been considered
inantidepressanttrialsaretheincreasingexpectationsfor
greater efficacy on the part of study participants, statis-
tical ‘‘regression to the mean’’ for participants who enter
a study when fluctuating symptom severity is at its high-
est, findings that higher dosing frequency results in
greater placebo response, and the fact that participants
who fail to improve are more likely to drop out of a study
early. An additional issue isthe question ofwhether newer
compounds, with fewer side effects, may be less ‘‘detect-
able’’ to participants, thus decreasing the inherent
positive bias toward the active compound and overall
drug-placebo differences in response. In conclusion,
S.D. suggested that the placebo response must be consid-
ered in the broader context of ‘‘signal detection’’ and that
the focus must remain on methods to improve the deter-
mination of efficacy (the ‘‘signal’’) independent of the
‘‘noise’’ introduced by placebo response.
Search for the Causes
In the interest ofidentifying contributingor ‘‘causal’’ fac-
tors,sessionchairsA.H.K.andN.R.S.presentedanover-
view of the relevant issues raised in the earlier discussions
and introduced additional factors for consideration.
Among the factors discussed were specific participant
characteristics (eg, gender, treatment resistance and
previous exposure, medication adherence, diagnostic ac-
curacy, illness severity), site characteristics (eg, academic
or commercial, experience and training of personnel,
recruitmentpressuresandprocedures,‘‘recycling’’ofsub-
jects),trialdesignissues(eg,entryrequirements,timingof
assessments,double-blindplacebolead-in,allowablecon-
comitant medications), clinical treatment setting (inpa-
tient or outpatient), and the reliability/generalizability
ofexistingoutcomemeasuresandassessmentinstruments.
Discussions among the session participants about these
issues were primarily directed at the imperative to over-
come methodological obstacles but were also well bal-
anced with ethical concerns for study participants,
minimization of risks, and optimization of the ‘‘real-
world’’clinicalapplicability/generalizabilityofstudyout-
comes(foradditionalin-depthdiscussionsofsomeofthese
issues, see Leucht et al,
7 Reidel et al,
8 or Hoffer et al
9)
R.A. highlighted the importance of study design fac-
tors. Specifically, the issue of allowable concomitant
treatments and ‘‘rescue’’ medications was reviewed
within the context of a recent RCT. The use of benzodia-
zepines, in particular, warrants careful consideration be-
cause their use may introduce confounds in interpreting
efficacy. The exclusion of benzodiazepines appears to
lead to higher dropout rates due to lack of efficacy in
theplacebogroupbutsimplifiestheinterpretationofstudy
outcome by eliminating the potential for synergistic (or
unpredictable) interactions with the experimental com-
pound.R.A.alsocommentedthattheequivalenceoftrials
conductedwithinandoutsideoftheUnitedStatesmustbe
evaluated more thoroughly before reaching conclusions
about whether the differences that have been previously
discussed will persist. For example, if differences are a
function of greater use of atypical antipsychotics, these
differences may diminish in time because clinical practice
trends currently seen in the United States may rapidly
spread to other regions throughout the world.
These discussions did not lead to a general consensus
among participants regarding a single or prominent
cause. However, there was a consensus that additional
progress could be made if data from more trials could
be evaluated. The presentations on which the evidence
of diminished differences rested were based on anecdotal
evidence or data from 1 or 2 trials. The general recom-
mendation from session participants was that the field
should collaborate to share data from multiple failed
and successful trials (appropriately deidentified to pro-
tect commercial interests) so that questions such as these
can be answered using robust data from different pro-
grams. By definition, some trials may fail due to statisti-
cal chance alone (1 in 20 given a .05 a), but the majority
of failed trials are probably attributable to a combination
of methodological factors. Thus, the focus of the final
portion of the joint session was on presenting statistical
and methodological perspectives that could be meaning-
fully applied in future RCTs.
Potential Solutions
A.V. provided a detailed presentation on the use of ad-
vanced pharmacokinetic (PK) and pharmacodynamic
(PD) modeling and simulation as a strategy to determine
the dose of antipsychotic medication that should maxi-
mize separation between side effects (eg, extrapyramidal
symptoms, prolactin increases, and other adverse events)
and efficacy (eg, PANSS improvement or dopamine
receptor occupancy level as an intermediate indicator)
while still differentiating from placebo responses. Specif-
ically, population-based PK/PD modeling and simula-
tion can provide a priori projections to guide the
design of RCTs (ie, dose selection, timing of efficacy
measures,etc)inamannerthat shouldoptimizetheprob-
ability that a given study will detect the ‘‘signal’’ of the
compound, despite the ‘‘noise’’ of placebo response. Fur-
thermore, A.V. also reviewed how advanced mixed-
effects models that take many relevant aspects into
account (eg, participant characteristics, disease pro-
gression, treatment effects, placebo effects, differential
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invaluable insight into the parameters that contribute
most directly to response rate differences among partic-
ipants. Collectively, advanced methods of modeling and
simulation are relatively underutilized analytic tools
that could contribute directly to overcoming existing
obstacles in detecting drug-placebo differences in
antipsychotic clinical trials.
The refinement of assessment instruments may also
provide a way to improve detection of differences.
This has become a familiar topic in forums addressing
clinical trial methodology. In a review of the importance
of such issues, A.C.L. presented a statistical perspective
on how improved assessment procedures directly trans-
lates into increased power to detect changes across
time and between treatment arms. According to the
Guidelines for Statistical Practice from the Committee
on Professional Ethics (American Statistical Association,
1999), researchers should ‘‘avoid the use of excessive or
inadequate numbers of research subjects by making in-
formed recommendations for study size.’’ Such informed
recommendations stem from statistical power analyses,
which for most clinical trial designers means increasing
sample sizes until the power is sufficient to detect statis-
tically significant change.
Alternatively, substantial improvements in the reliabil-
ity of assessment procedures can result in decreased
within-group variability, increased between-group effect
sizes, and consequently smaller sample size requirements
to achieve acceptable statistical power.
10–12 This precept
was illustrated in a poster, presented at the session
by A.S.K., which suggested that the improved reliability
afforded by computerized administration of neurocogni-
tive assessments could result in a 28% reduction in the
sample size required to detect a 10% improvement on
these measures. This estimate was derived from the
respective means and SDs obtained in a direct compari-
son of test-retest reliability and concurrent validity be-
tween standard and computerized administration of
a representativebattery ofneurocognitive tests, including
those selected by the Clinical Antipsychotic Treatment
Intervention Effectiveness (CATIE) and Measurement
And Treatment Research to Improve Cognition in
Schizophrenia(MATRICS)consortia.
13A.C.L.alsopro-
vided evidence that within-group variance could be sub-
stantially reduced by enhancing interrater reliability and
ratings validity using a limited cadre of highly trained
raters who were blinded not only to treatment but also
to time point in the study. He described a method for
such assessments that uses raters at a central site who
are connected to study participants via a secured video
internet connection and showed data indicating im-
proved ability to detect drug-placebo differences.
The importance of site characteristics and potential
solutions for improving site performance was presented
by L.E. Among the many issues reviewed, the concern
that ‘‘professional’’ participants or rater inflation are
a unique problem for US-based sites was depicted as
somewhat premature, particularly because entrepreneurs
throughout the world will inevitably follow capital in-
vestment in this market. Therefore, the critical determin-
ing factors influencing site selection should be based on
individual site and investigator characteristics that indi-
cate the investigators’ commitment to ensure ethical,
nonbiased execution of study protocols. Included in
the attributes that L.E. suggested a ‘‘quality’’ site must
possess were staff with considerable clinical experience
working with the patient population and assessment
instruments employed, demonstrated ‘‘in-house’’ train-
ing procedures and quality assurance metrics, ongoing
programs to prevent rater drift and insure consistency
as staff turnover, a reliable source of participant recruit-
ment across a variety of settings, and facilities that are
appropriate to fully service the clinical needs of the par-
ticipants and requirements of the study. An additional
issue raised in discussion following this presentation
was the need for enhancing dialogue between the sponsor
and the participating sites to induce greater involvement
by the investigators in the planning and design aspects of
the study. In closing, L.E. stated that the ‘‘culture’’ of
Table 3. Summary of Possible Contributory Problems and Potential Solutions Proposed at the Meeting
Contributory Problems Potential Solutions
Subjects with longer duration of current acute episode
show poorer response to treatments.
Exclude subjects whose current acute episode exceeds 1 mo
prior to enrollment in study.
Use of ‘‘rescue medicines’’ such as benzodiazepines can
confound drug-placebo differences.
Exclude subjects who are concurrently ‘‘stabilized’’ on
benzodiazepines and prohibit concomitant use.
Variability in outcome assessments decreases statistical
power to detect drug-placebo differences across the study.
Increase reliability through improvements in assessment
administration/instrument design and rater training/
qualiﬁcation procedures.
Insufficient bases for selecting doses to be tested in
phase 3 studies may limit potential findings.
Use of pharmacokinetic/pharmacodynamic modeling to
optimize dosing regimes in trials.
Subjective reports of medication compliance are
notoriously unreliable in this population.
Explore new methods to measure medication compliance
and increase protocol adherence.
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investigator, which, in turn, is a critical determining
factor in the quality of the data that will result from
the study as a whole.
Following formal presentations, roundtable discus-
sions were conducted among the session participants
and a panel composed of L.E., R.A., M.D., J.-P.L.,
and A.C.L. These discussions were moderated by session
chairs, A.H.K. and N.R.S., and served as a platform for
debating the overall implications of the issues raised
throughoutthesessionamongarangeofexpertattendees
from industry, academia, clinical sites, and governmental
agencies. A poster session also served as an additional
outlet for the sharing of findings with direct relevance
to the issues discussed.
Conclusions
The first joint session between the ISCTM and the
ISCDD was brought to a conclusion by N.R.S. who
reviewed the relevant issues concerning the problem of
diminishing drug-placebo differences in acute schizo-
phrenia RCTs and potential solutions discussed (summa-
rized in table 3). Overall, shorter duration of current
exacerbation of symptoms (<1 month) seems to be a rel-
evant factor resulting in greater drug responses, as does
inpatient settings. Reducing the use of benzodiazepines
appears prudent, as do strategies to reduce sample size
requirements by improving assessment reliability, partic-
ularly because the latter represents an ethically responsi-
ble method to reduce placebo exposures to research
participants.Furtherfactorsthatseemreasonabletopur-
sue include improved methods to enhance and/or mea-
sure protocol adherence and medication compliance by
participants, increased site investigator involvement
and commitments to scientific rigor, and the credential-
ing of raters to ensure interviewing skills sufficient to
gauge the full breadth of symptoms that characterize
patients with schizophrenia. In closing, N.R.S. appealed
to the 2 societies’ respective members to develop larger
pooled data repositories that could be examined to iden-
tify potential sources of placebo responses on failed trials
and facilitate more in-depth meta-analyses such as that
recently reported by Leucht et al.
14 Because the interest
instigated by the industry’s needs for improved method-
ologies may be leveraged into greater scientific under-
standing with much larger implications, the pursuit of
solutions to this problem will serve to benefit both the
patients to be treated and society, as well.
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